Moinard-Butot Fabien, Nannini Simon, Fischbach Cathie, Abdallahoui Safa, Demarchi Martin, Petit Thierry, Bender Laura, Schott Roland
Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, 17 Rue Albert Calmette, 67033 Strasbourg, France.
Cancers (Basel). 2023 Oct 11;15(20):4940. doi: 10.3390/cancers15204940.
Lung cancers with ALK rearrangement represent less than 5% of all lung cancers. ALK inhibitors are currently used to treat first-line metastatic non-small cell lung cancer with ALK rearrangement. Compared to chemotherapy, ALK inhibitors have improved progression-free survival, overall survival, and quality of life for patients. The results of several phase 3 studies with a follow-up of over 6 years suggest that the life expectancy of these patients treated with targeted therapies is significantly higher than 5 years and could approach 10 years. Nevertheless, these treatments induce haematological toxicities, including neutropenia. Few data are available on neutropenia induced by ALK inhibitors and on the pathophysiological mechanism and therapeutic adaptations necessary to continue the treatment. Given the high efficacy of these treatments, managing side effects to avoid treatment interruptions is essential. Here, we have reviewed the data from published clinical studies and case reports to provide an overview of neutropenia induced by ALK inhibitors.
伴有间变性淋巴瘤激酶（ALK）重排的肺癌占所有肺癌的比例不到5%。ALK抑制剂目前用于治疗一线转移性ALK重排非小细胞肺癌。与化疗相比，ALK抑制剂改善了患者的无进展生存期、总生存期和生活质量。几项随访超过6年的3期研究结果表明，接受靶向治疗的这些患者的预期寿命显著高于5年，可能接近10年。然而，这些治疗会引发血液学毒性，包括中性粒细胞减少。关于ALK抑制剂所致中性粒细胞减少以及继续治疗所需的病理生理机制和治疗调整的数据很少。鉴于这些治疗的高效性，管理副作用以避免治疗中断至关重要。在此，我们回顾了已发表的临床研究和病例报告中的数据，以概述ALK抑制剂所致中性粒细胞减少。
